News

Jun 27, 2025

Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection

➞

Jun 26, 2025

Mabwell Bioscience and Calico Life Sciences Announce Exclusive Licensing Agreement for Novel IL-11 Targeting Monoclonal Antibody

➞

Jun 04, 2025

Highlights in Poster Presentations of Mabwell at 2025 ASCO

➞

Jun 04, 2025

Highlights in Oral Presentation of Mabwell's 9MW2821 at 2025 ASCO

➞

May 29, 2025

Mabwell Receives NMPA Approval for Albipagrastim alfa for Injection (MAILISHENG)

➞

May 23, 2025

Mabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting

➞

Apr 30, 2025

Mabwell Releases 6 Study Results of Innovative Drugs and Platforms at the 2025 AACR Annual Meeting

➞

Apr 24, 2025

Mabwell to Present Clinical Data of 9MW2821 Combined with Toripalimab in Patients with UC in an Oral Presentation at 2025 ASCO

➞

Apr 14, 2025

Mabwell and DP Technology Announces Strategic Cooperation to Build a New Research Paradigm for R&D of Innovative Drug

➞

Apr 02, 2025

Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor

➞